Today, the SVP & CFO of Codexis (CDXS), Gordon Sangster, bought shares of CDXS for $299.6K.
This recent transaction increases Gordon Sangster’s holding in the company by 84.7% to a total of $2.81 million. Following Gordon Sangster’s last CDXS Buy transaction on January 28, 2019, the stock climbed by 3.9%.
See today’s analyst top recommended stocks >>
Currently, Codexis has an average volume of 325.4K. The Company has a Price to Book ratio of 18.8391.
Starting in May 2018, CDXS received 14 Buy ratings in a row. Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.50, reflecting a 14.7% upside. Three different firms, including Craig-Hallum and Jefferies, currently also have a Buy rating on the stock.
The insider sentiment on Codexis has been neutral according to 51 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics.
